<SEC-DOCUMENT>0001628280-23-004613.txt : 20230222
<SEC-HEADER>0001628280-23-004613.hdr.sgml : 20230222
<ACCEPTANCE-DATETIME>20230222172413
ACCESSION NUMBER:		0001628280-23-004613
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230222
FILED AS OF DATE:		20230222
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		23654701

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk02x22x2023.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8f55e0167c1a4757b18231e0af3e80ec_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of February, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)&#58; ____</font></div><div><font><br></font></div><div style="margin-bottom:11.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </font></div><div style="margin-bottom:11.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)&#58; ____ </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58; Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 22, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="cybinannouncesstreamlinedc.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated February 22, 2023</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cybinannouncesstreamlinedc.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia2095ee93ed34e4ab43f2138aa9a1f25_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.05pt;margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.25pt;text-align:justify"><font><br></font></div><div style="margin-top:4.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Cybin Announces Streamlined Clinical Alignment </font></div><div style="margin-top:4.6pt;padding-left:36pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">-  Company streamlining to fully focus on achieving near-term, mid-term and long-term clinical milestones -</font></div><div style="margin-top:4.6pt;padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">This news release constitutes a &#8220;designated news release&#8221; for the purposes of</font></div><div style="margin-top:4.6pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cybin&#8217;s prospectus supplement dated August 8, 2022 to its short form base shelf</font></div><div style="margin-top:4.6pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">prospectus dated July 5, 2021</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:161%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">&#8211; February 22, 2023 &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%"> (NEO&#58;CYBN) (NYSE American&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:161%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:161%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">&#8221;), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:161%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%"> today announced a streamlining plan aimed at maximizing the Company&#8217;s operating efficiency and to allow the Company to focus on critical clinical trials.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">Based on anticipated cost savings from the streamlining exercise and the Company&#8217;s ongoing and previously announced US$35 million At-The-Market (&#8220;ATM&#8221;) equity program, management believes the Company will be better positioned for both near-term and long-term success.  The Company anticipates these cost savings will result in a decrease in its historical annual cash burn rate by millions of dollars, while Cybin continues to push forward on all core clinical initiatives.  </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">Today, the Company has released approximately 15% of its workforce that previously held roles that were not of a clinical priority or were not directly involved with any of the Company&#8217;s clinical trial initiatives.  As a result of the headcount reductions, the Company expects to generate cost savings from reducing operating expenses. </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">The Company has evolved from the discovery-stage into clinical-stage operations, and this prioritized clinical alignment allows the Company to, among other things, leverage intellectual property generated from its discovery efforts for clinical development, and focus on clinical execution. </font></div><div style="margin-top:12.6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">&#8220;The Company has made the prudent decision to evaluate every role within its workforce, including whether certain tasks could be performed more efficiently while ensuring that the Company&#8217;s core clinical activities continue to be robustly supported and resourced.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">We appreciate the significant contributions of our employees and the hard work they performed for the Company and understand the impact that this difficult decision has on them. We are committed to maintaining a lean organization and will continue to make clinical trial execution in support of our proprietary molecules our top priority&#8221; said Doug Drysdale, Chief Executive Officer of Cybin.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">The Company&#8217;s actions today are expected to better support upcoming value-driving clinical milestones and the development of the Company&#8217;s differentiated therapeutics for mental health disorders. The Company continues to pursue the goal of bringing improved therapeutic options to patients in need.   </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">The Company reminds investors that it will host a virtual R&#38;D Day on Tuesday, February 28, 2023, from 10&#58;00 a.m. ET to 11&#58;30 a.m. ET. The event, which will be hosted by Cybin&#8217;s leadership team, will provide a progress update on the Company&#8217;s development pipeline of differentiated psychedelic-based therapeutics, including CYB003 and CYB004. Specifically, the Company plans to provide an interim readout from the ongoing Phase 1&#47;2a study evaluating CYB003, an update from the ongoing Phase 1 exploratory CYB004-E trial evaluating IV N,N-dimethyltryptamine and a review of its clinical development program evaluating CYB004. Cybin is evaluating CYB003 for the treatment of major depressive disorder and CYB004 is being evaluated for the treatment of generalized anxiety disorder.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">To participate in the event, please </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%;text-decoration:underline">click here </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">to register and access the live webcast. A Q&#38;A session for the investment community will follow the prepared remarks. The archived webcast will also be available on the Company&#8217;s investor relations website page following the event on the </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%;text-decoration:underline">Events &#38; Presentations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%"> page.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Cybin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221; or &#8220;continue&#8221;, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the ATM program&#59; the Company&#8217;s expectation to generate costs savings on a run rate basis as a result of its streamlining efforts&#59; the Company&#8217;s pursuit of bringing improved therapeutic options to patients in need&#59; the Company&#8217;s better support for upcoming value-driving clinical milestones and the development of the Company&#8217;s differentiated therapeutics&#59; the Company&#8217;s ability to preserve its cash position&#59; the Company&#8217;s ability to raise additional funds under the ATM program or otherwise&#59; the Company&#8217;s plans to provide an interim readout from the CYB003 Phase 1&#47;2a study&#59; the Company&#8217;s plans to provide an update on the CYB004-E trial and the CYB004 program&#59; the Company&#8217;s anticipated results of CYB003 and CYB004&#59; the Company&#8217;s ability to reduce its historical annual cash burn by millions of dollars as a result of its transition from the discovery stage into clinical stage operations and corresponding headcount reductions&#59; and the Company&#8217;s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. </font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; implications of the COVID-19 pandemic on the Company's operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.05pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">month periods ended December 31, 2022, the Company&#8217;s annual  information form for the year ended March 31, 2022, and the Company&#8217;s listing statement dated November 9,  2020 which are available under the Company's profile on www.sedar.com</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward- looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward- looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:154%">Non-GAAP Financial Measures</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">In this press release, Cybin refers to certain non-GAAP financial measures, including annual cash burn rate. These measures do not have any standardized meaning in accordance with GAAP and may not be comparable to similar measures presented by other companies. Cybin considers certain non-GAAP measures to be meaningful indicators of the performance of its business. These measures are not recognized measures under GAAP, do not have a standardized meaning prescribed by GAAP and may not be comparable to (and may be calculated differently by) other companies that present similar measures. Accordingly, these measures should not be considered in isolation from nor as a substitute for the Company&#8217;s financial information reported under GAAP.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:161%">Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:161%"></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:161%">Investor &#38; Media Contact&#58;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:161%">Leah Gibson</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">Vice President, Investor Relations &#38; Strategic Communications</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">Cybin Inc.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%"> &#8211; or &#8211; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%;text-decoration:underline">media&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%"> </font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">Gabriel Fahel</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">Chief Legal Officer</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">Cybin Inc.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:154%">1-866-292-460</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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ML]F 1I&A9$"=;*->WUZ>I)]=ZW22",.#4(=DV&QP[C6TB%A,W"65<RL5P;S
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MII))7L'59&NK<Q1R?WV9_L& R/O^6;/1Z#A=5K:6W]/6]"0S!"R<7I)W&<C
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M*H$>MQY;7SE"V96(^!W>Q>QB.63%-?I$52Y4L;$@U[_AO:80/T5O:R"!B__
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M6EQ+?1$N2,<_EXR2)BKY-&XO3Y+G>VOY?7QMCC0G2;/B.I=A#^A30GK'3S\
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M;AA:''@"LW_3)\*BK:_OH2T$<30F3K;1J'LGGM&OBICB:S8+LS?E_NYZA[/
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M3M:QW-]=IR*NS2_CP;G7@=F_PPO_' 2^5\M%^#L$0:SD_P.!FI"CC7N0 P
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
